spartalizumab spartalizumab spartalizumab (inn; development code pdr001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma. spartalizumabmonoclonal antibodytypewhole antibodysourcehumanizedtargetpd-1 (cd279)clinical dataother namespdr001atc codenoneidentifierscas number1935694-88-4uniiqog25l6z8zkeggd11605 this drug is being developed by novartis. as of 2018, spartalizumab is undergoing phase iii trials.